Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy Meeting Abstract
| Authors: | De Wit, R.; Powles, T.; Castellano, D. E.; Necchi, A.; Lee, J. L.; Van Der Heijden, M. S.; Matsubara, N.; Bamias, A.; Flechon, A.; Sternberg, C. N.; Drakaki, A.; Yu, E. Y.; Hamid, O.; Zimmermann, A.; Gao, L.; Long, A.; Walgren, R. A.; Bell-McGuinn, K. M.; Petrylak, D. P. |
| Abstract Title: | Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 247s |
| Language: | English |
| ACCESSION: | WOS:000442916002053 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4526 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4526 -- Source: Wos |
